Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7411 to 7425 of 7675 results

  1. Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]

    In development [GID-TA11569] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Atezolizumab with chemotherapy for untreated recurrent or advanced endometrial cancer [ID6417]

    Discontinued [GID-TA11522]

    Technology appraisal guidance
    Discontinued

  3. Microstructural scaffold (patch) insertion without autologous cell implantation for repairing symptomatic chondral knee defects (IPG560)

    This guidance has been updated and replaced by NICE interventional procedures guidance 793.

    Interventional procedures guidance
    Published
    22 June 2016

  4. Pembrolizumab–vibostolimab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer [ID6361]

    In development [GID-TA11401] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Cox-II inhibitors for the treatment of osteoarthritis and rheumatoid arthritis (TA27)

    This guidance has been replaced by NICE guideline CG59 and NICE guideline CG79.

    Technology appraisal guidance
    Published
    23 July 2001

  6. Psoriatic arthritis in adults: certolizumab pegol (ESNM42)

    This evidence summary has been updated and replaced by NICE technology appraisal guidance 445.

    Evidence summary
    Published
    24 June 2014

  7. The MAGEC system for spinal lengthening in children with scoliosis (MTG18)

    August 2024: Following the lifting on the UK suspension of MAGEC system (modified MAGEC X system), NICE's prioritisation board will be reviewing the guidance that was withdrawn in April 2020. We will update this page once a decision is made.

    Medical technologies guidance
    Published
    18 June 2014

  8. Peezy Midstream for urine collection (MT446)

    In development [GID-MT538] Expected publication date: TBC

    Medical technologies guidance
    In development

  9. Peezy Midstream for urine collection (MIB183)

    NICE has withdrawn the med tech innovation briefing (MIB) on Peezy Midstream for urine collection because there is published evidence that shows it offers no clinical benefits over standard care (clean catch method).

    Medtech innovation briefing
    Published
    8 May 2019

  10. Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for early triple negative breast cancer [ID6200]

    In development [GID-TA11165] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Azacitidine for treating relapsed or refractory angioimmunoblastic T-cell lymphoma [ID3864]

    Discontinued [GID-TA10750]

    Technology appraisal guidance
    Discontinued

  12. Lurbinectedin for treating advanced small-cell lung cancer on or after platinum-based chemotherapy [ID3872]

    In development [GID-TA10758] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Atezolizumab for adjuvant treatment of high-risk locally advanced squamous cell head and neck cancer [ID4052]

    In development [GID-TA10933] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Sacituzumab govitecan for treating unresectable metastatic urothelial cancer [ID6150]

    In development [GID-TA11009] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Surgical correction of hallux valgus using minimal access techniques (IPG332)

    This guidance has been updated and replaced by NICE interventional procedures guidance 789. 

    Interventional procedures guidance
    Published
    24 February 2010